Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Numinus Wellness Inc T.NUMI

Alternate Symbol(s):  NUMIF

Healthcare
Numinus Wellness Inc. is a mental health care company. The Company focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and... see more

Recent & Breaking News (TSX:NUMI)

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

PR Newswire November 29, 2021

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

PR Newswire November 26, 2021

Numinus Announces Departure of Stacey Wallin

PR Newswire November 25, 2021

Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021

PR Newswire November 22, 2021

Numinus to Begin Trading on the OTC Under Symbol NUMIF

PR Newswire November 19, 2021

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

PR Newswire November 10, 2021

Numinus to Participate in Microdose Hosted Events: Psychedelic Capital and Wonderland: Miami

PR Newswire October 26, 2021

The StockTalk Cannabis Report: Oct 22, 2021

Dave Jackson October 22, 2021

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

PR Newswire October 20, 2021

Psychedelic Therapies: Bringing Clinical Results into the Real World

Stockhouse Editorial October 19, 2021

Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities

PR Newswire October 8, 2021

Numinus Completes Acquisition of Neurology Centre of Toronto

PR Newswire September 23, 2021

Numinus to Participate in Upcoming Investor Conferences in September 2021

PR Newswire September 2, 2021

CORRECTION FROM SOURCE: BTV Examines the Rapidly Expanding Psychedelics Market

Newsfile August 17, 2021

BTV Examines the Rapidly Expanding Psychedelics Market

Newsfile August 17, 2021

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology

PR Newswire July 29, 2021

Numinus announces Health Canada approval of MAPS-Sponsored open label study for MDMA-Assisted therapy for PTSD

Stockhouse Editorial July 13, 2021

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD

PR Newswire July 12, 2021

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology

PR Newswire July 6, 2021

Numinus Announces Grant of Stock Options

Canada NewsWire June 24, 2021